Project Grant R01AG087356

Award Date 6/15/24
Completion Date 2/28/29
Dollars Obligated $4.3M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) for $2,273,637 aims to conduct a comprehensive lipidomics study to investigate the relationship between plasma and brain lipid profiles, cognitive decline, and the onset of Alzheimer's disease (AD) and other dementias. The study will leverage the Cardiovascular Health Study cohort to examine the association of plasma lipidomic species with risks of incident AD, total dementia, and cognitive decline. It...
This Project Grant award, valued at $2,380,018.00, was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to the Regents of the University of Michigan. The overarching goal is to investigate the influence of cumulative hyperglycemia, type 2 diabetes management, and vascular risk factors on cognitive decline and Alzheimer's disease and related dementias (ADRD) risk. The research team will leverage pooled cohort studies and individual participant data meta-analysis to...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $622,000 in funding to the University of Maryland, Baltimore to investigate the role of mitochondrial complex I deficiency in the development of Alzheimer's disease and dementia. The key objectives are to: 1) Determine the effects of complex I deficiency on humanized amyloid beta proteinopathy, a hallmark of Alzheimer's disease, and 2) Assess the susceptibility of complex I-deficient...
The National Institute on Aging (NIA) awarded a $2,330,235 Project Grant (CFDA 93.866 - Aging Research) to Rush University Medical Center in Chicago, IL to examine the relationship between diet, neuroinflammation, brain oxidative stress, and plasma neurodegenerative biomarkers. The 5-year project, beginning in Sep 2024, aims to elucidate the link between diet and Alzheimer's disease/age-related dementias (AD/ADRD) by leveraging data from four longitudinal community cohorts. Key objectives...
This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...
This Project Grant award of $812,030.00 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop and optimize non-invasive imaging biomarkers to track neuroinflammation in the early stages of Alzheimer's disease (AD). The research comprises three key components: Investigating the relationship between astrocytic acetate metabolism and astrocyte reactivity in an adenovirus-induced reactive astrogliosis model, utilizing...
This $326,797 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to identify proteomic (protein-based) biomarkers that can predict risk of cognitive impairment in individuals with type 2 diabetes. The primary goal is to use proteomic analyses to discover plasma protein differences and networks associated with newly diagnosed mild cognitive impairment in this population. The project will also examine how these proteins relate to preclinical...
The National Institute on Aging (NIA) awarded Emory University a $528,876 Project Grant under the Aging Research federal grant program (CFDA 93.866) to develop new analytical tools that can identify more Alzheimer's disease (AD) and AD-related dementia (ADRD) risk genes by integrating genome-wide association study (GWAS) data with transcriptome-wide association study (TWAS) and proteome-wide association study (PWAS) data across multiple brain tissues. The key products and services to be...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $630,905 to the University of Wisconsin - Madison to explore the role of the gut microbiome-derived metabolite imidazole propionate (IMP) in the progression of Alzheimer's disease (AD) and related dementias (ADRD). The key objectives are to characterize the relationship between IMP, blood-brain barrier disruption, and AD pathology in mouse models, as well as determine the association between IMP...
This Cooperative Agreement award from the National Institute on Aging (under CFDA 93.866 - Aging Research) provides $2,533,483 to The Trustees of Columbia University in the City of New York to study the impact of environmental toxicants on the risk of Alzheimer's disease (AD) and AD-related dementias (ADRD) among participants in the Diabetes Prevention Program Outcomes Study (DPPOS) AD/ADRD project. The key products and services to be delivered under this grant include: (1) conducting...

IDENTIFICATION OF BRAIN METABOLOMIC PROFILES ASSOCIATED WITH DEMENTIA - PROJECT SUMMARY/ ABSTRACT IDENTIFYING MECHANISTIC PATHWAYS UNDERLYING ALZHEIMER'S DISEASE/ALZHEIMER'S DISEASE-RELATED DEMENTIAS (AD/ADRD) IS CRITICAL TO DISCOVERING NEW TARGETS TO TEST FOR PREVENTIVE AND THERAPEUTIC INTERVENTIONS. METABOLIC DYSREGULATION, BOTH SYSTEMIC (E.G., DIABETES) AND CEREBRAL (E.G., DYSFUNCTIONAL LIPID/INSULIN SIGNALING), IS ASSOCIATED WITH HIGHER DEMENTIA RISK AND AD-RELATED NEUROPATHOLOGY. GROWING EVIDENCE FROM GENETIC AND MOLECULAR RESEARCH, AND INITIAL STUDIES OF METABOLOMIC PROFILING IN POSTMORTEM BRAIN TISSUE, COLLECTIVELY INDICATE THAT METABOLIC MECHANISMS MAY UNDERLIE AD/ADRD. HOWEVER, THE SPECIFIC BRAIN METABOLIC PATHWAYS INVOLVED IN AD/ADRD ARE NOT WELL-UNDERSTOOD; AND CRITICAL RESEARCH GAPS REMAIN. FIRST, EXISTING METABOLOMIC STUDIES IN BRAIN TISSUE - THE TARGET ORGAN OF DEMENTIA - HAVE MODEST SAMPLE SIZES AND LIMITED REPLICATION. SECOND, DEEPER INTERROGATION IS NEEDED FOR BRAIN BIOCHEMICALS THAT APPEAR RELATED TO BRAIN FUNCTION (E.G., COMPLEX LIPIDS AND FATTY ACIDS, LIPID MEDIATORS OF INFLAMMATION, GUT MICROBIOME-RELATED NEUROCHEMICALS, GLUCOSE/BIOENERGETIC METABOLITES). FINALLY, THE PLAUSIBLE CAUSAL ROLE OF BRAIN METABOLIC REGULATION IN DEMENTIA IS YET TO BE EXPLORED. THE OVERARCHING GOAL OF THIS PROPOSAL IS TO COMPREHENSIVELY EXAMINE BRAIN METABOLITES ASSOCIATED WITH COGNITIVE DECLINE. SPECIFICALLY, WE WILL USE CLINICAL, NEUROPATHOLOGIC, AND GENOMIC DATA, AS WELL AS POSTMORTEM BRAIN TISSUE FROM 1,200 DECEASED INDIVIDUALS FROM TWO COMMUNITY-BASED AGING COHORTS - THE RELIGIOUS ORDERS STUDY (ROS) AND RUSH MEMORY AND AGING PROJECT (MAP). FOR THE PROPOSED RESEARCH, WE WILL LEVERAGE EXISTING BRAIN METABOLOMIC DATA IN ROSMAP, AND STRATEGICALLY GENERATE NEW DATA BY EXTENDING THE SAMPLE SIZE AS WELL AS METABOLITES PROFILED -- ALLOWING US TO EXAMINE A TOTAL OF ~1,800 METABOLITES ACROSS THREE PLATFORMS. IN AIM 1, WE WILL USE AGNOSTIC DISCOVERY TO IDENTIFY AND THEN INDEPENDENTLY REPLICATE METABOLITES AND METABOLOMIC COREGULATORY NETWORKS ASSOCIATED WITH COGNITIVE DECLINE; AND WE WILL INTEGRATE GENETIC DATA USING MENDELIAN RANDOMIZATION ANALYSES TO INFER PLAUSIBLE CAUSALITY. IN ADDITION, AS A NOVEL APPROACH TO DISCOVERY, IN AIM 2, WE WILL ANCHOR DISCOVERY TO A METABOLIC RISK FACTOR FOR DEMENTIA. SPECIFICALLY, DIET IS INTEGRAL TO METABOLISM, AND HEALTHY DIETARY PATTERNS ARE ASSOCIATED WITH SLOWER COGNITIVE DECLINE AND LOWER DEMENTIA RISK; THUS, WE WILL IDENTIFY BRAIN METABOLOMIC PROFILES ASSOCIATED WITH HEALTHY DIETARY PATTERN IN MAP, AND THEN TEST THESE PROFILES IN RELATION TO COGNITIVE DECLINE IN ROS. WE HAVE SUCCESSFULLY UTILIZED SUCH APPROACHES IN OUR PRIOR WORK. FINALLY, IN THE EXPLORATORY AIM 3, WE WILL IDENTIFY METABOLOMIC PROFILES ASSOCIATED WITH COGNITIVE RESILIENCE (THE ABILITY TO MAINTAIN COGNITION DESPITE THE PRESENCE OF NEUROPATHOLOGY). IMPACT: LED BY AN EARLY- STAGE INVESTIGATOR AND SUPPORTED BY AN INTERDISCIPLINARY TEAM OF EXPERIENCED RESEARCHERS, THIS PROPOSAL IS POISED TO DISCOVER NOVEL BRAIN METABOLIC PATHWAYS ASSOCIATED WITH COGNITIVE HEALTH, AND PROVIDE NEW EVIDENCE THAT MAY INFORM NOVEL INTERVENTIONS. IN ADDITION, WE WILL GENERATE EXTENSIVE BRAIN METABOLOMICS DATA TO SHARE WITH THE SCIENTIFIC COMMUNITY, YIELDING A SIGNIFICANT AND SUSTAINED IMPACT ON THE FIELD.

Posted 6/14/24, 12:00 AM